Please try another search
For the nine months ended 30 September 2021, AdamasPharmaceuticals Inc revenues increased 26% to $67.2M. Netloss increased 14% to $44.4M. Revenues reflect Productsales increase of 23% to $63.1M, Royalty revenue increaseof 99% to $4.1M. Higher net loss reflects Other General andAdministrative. increase of 16% to $80.3M (expense),Stock-based Compensation in General increase of 16% to$5.2M (expense).
Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Total Revenue | 25.9 | 21.97 | 19.31 | 21.01 |
Gross Profit | 25.32 | 21.45 | 18.93 | 20.41 |
Operating Income | -5.64 | -9.15 | -9.53 | -14.98 |
Net Income | -19.52 | -12.34 | -12.57 | -18.27 |
Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Total Assets | 143.98 | 150.64 | 169.25 | 120.03 |
Total Liabilities | 165.58 | 154.68 | 163.31 | 170 |
Total Equity | -21.61 | -4.03 | 5.94 | -49.98 |
Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -36.49 | -30.24 | -21.06 | -50.71 |
Cash From Investing Activities | -22.07 | -19.06 | 7.79 | 54.94 |
Cash From Financing Activities | 65.52 | 66.44 | 66.44 | 1.65 |
Net Change in Cash | 6.96 | 17.14 | 53.17 | 5.89 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review